Thursday, May 29, 2014 - 13:05
On May 27, 2014, the United States Preventive Services Task Force (USPSTF) released its final recommendations on hepatitis B screening of non-pregnant adolescents and adults.
Wednesday, May 14, 2014 - 13:30
Call your Members of Congress and urge them to take action in support of National Hepatitis Testing Day!
Tuesday, May 6, 2014 - 14:01
NVHR and our partners are hosting a National Hepatitis Testing Day event at the U.S. Capitol on May 19, 2014.
Tuesday, April 29, 2014 - 11:25
The Patient Assistance Network (PAN) Foundation has developed a flyer with information about its financial assistance support for patients with hepatitis B and C to help cover medication out-of-pocket costs.
Thursday, April 3, 2014 - 08:15
We are excited to announce a survey to inform the first program work of NVHR!
Monday, March 31, 2014 - 08:11
Urge Your Senator To Sign Important Appropriations Letter
Senator Jeff Merkley (D-OR) is asking all Senators to sign an important letter supporting increased funding for viral hepatitis programs in the Fiscal Year 2015 appropriations bill (see text of letter below and in attached document).
Tuesday, February 25, 2014 - 09:09
NVHR's letter to State Medicaid Directors urging them to use AASLD/IDSA hepatitis C treatment guidelines when making drug formulary decisions.
Friday, February 14, 2014 - 15:45
Attached a press release from WHO, from last week, which raises liver cancer up to the 2nd leading cause of cancer death worldwide (after lung cancer). It was previously 3rd. This is very compelling evidence to use as we strive to include liver cancer more in our messaging and talks
with our federal/national partners.
Monday, February 3, 2014 - 14:31
Sample letter for medical providers for insurance company denial of treatment using two new FDA approved drugs to treat chronic hepatitis C, Olysio (simeprevir) and Sovaldi (sofosbuvir)
Monday, February 3, 2014 - 14:28
Read NVHR's letter to medical providers regarding the appeals process to appeal insurance company denial of treatment using two new FDA approved drugs to treat chronic hepatitis C, Olysio (simeprevir) and Sovaldi (sofosbuvir)